Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Dry Eye Treatment Mucosta Ophthalmic Suspension Approved: Otsuka
September 27, 2011
- Teva to Resolve Joint Venture with Kowa, Acquire 100% Stake in Teva-Kowa
September 27, 2011
- Japan’s First Oral MS Treatment Imusera/Gilenya Approved: MTPC/Novartis
September 27, 2011
- Prazaxa Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
September 27, 2011
- Breast Cancer Treatment Faslodex Approved: AZ
September 27, 2011
- BMS to File for Apixaban for Stroke Prevention in Japan, US, and Europe Before Year-end
September 27, 2011
- COPD Treatment NVA237 Filed in Europe by Novartis: Sosei
September 27, 2011
- Novartis Announces New PIII Data for Inhaled Therapy NVA237 at ERS Congress
September 27, 2011
- Daiichi Sankyo Unable to Ship 2.36 million Vials of Flu Vaccine Due to Virus Contamination
September 26, 2011
- OncoTherapy To Receive Milestone Payment following Submission of PI Clinical Trial Certificate
September 26, 2011
- Shanghai Genomics Receives New Drug Certificate for the Treatment of IPF in China
September 26, 2011
- Astellas: OAB Treatment Betanis Tablets
September 26, 2011
- Ono/Astellas: Once-Every-Four-Weeks Formulation of Recalbon, Bonoteo
September 26, 2011
- MTPC, Janssen Pharma Launch RA Treatment Simponi
September 26, 2011
- Vibativ Approved in Europe for Treatment of Nosocomial Pneumonia: Astellas
September 26, 2011
- 60% of License Agreements Cancelled Due to Changes in Partners’ Business Strategy
September 26, 2011
- Daiichi Sankyo Announces Delay in Flu Vaccine Shipment Due to Possible Contamination
September 26, 2011
- Ajinomoto Files Suit over Actonel Generic Seeking Suspension of Sales
September 26, 2011
- Trans Genic Files Patent Application for Antibody against Novel Lung Cancer Marker
September 26, 2011
- US FDA Completes Review of Protocol for PIII Trial of Collategene: AnGes MG
September 26, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…